Infigratinib phosphate

• Description :

  Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

• CAS Number :

  [1310746-10-1]

• Product Name Alternative :

  BGJ-398 phosphate; NVP-BGJ398 (phosphate)

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  FGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/NVP-BGJ398-phosphate.html

• Concentration :

  10mM

• Purity :

  99.59

• Solubility :

  DMSO : 8.75 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=P(O)(O)O.ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O

• Molecular Formula :

  C26H34Cl2N7O7P

• Molecular Weight :

  658.47

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Guagnano V, et al. Discovery of 3- (2,6-Dichloro-3,5-dimethoxy-phenyl) -1-{6-[4- (4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T|[2]Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12 (5) :632-42.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  BioRxiv. 2025 Nov 14.|Ann Rheum Dis. 2016 May;75 (5) :883-90. |Anti-Cancer Drug. 2022 Dec.|Biochim Biophys Acta Mol Basis Dis. 2025 May 29:167940.|Biomed Pharmacother. 2025 Oct 21:192:118677.|Biomedicines. 2023 Nov 27;11 (12) :3155.|bioRxiv. 2024 May 14.|bioRxiv. 2025 Jun 16:2025.06.11.659120.|Biotechnol J. 2024 Aug;19 (8) :e2400278.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2019 Dec;9 (12) :1686-1695.|Cancers (Basel) . 2024 Jul 3;16 (13) :2447.|Cell Death Dis. 2025 Jul 2;16 (1) :485.|Cell Rep. 2024 Dec 30;44 (1) :115116.|Cell Rep. 2019 Feb 12;26 (7) :1709-1717.e3. |Chem Res Toxicol. 2021 Jul 19;34 (7) :1800-1813.|Department Biologie. Friedrich-Alexander University Erlangen-Nuremberg. March.10th.2016.|Development. 2025 May 15;152 (10) :dev204687. |FEBS Open Bio. 2023 May;13 (5) :804-817.|Heliyon. 2024 May 10.|J Control Release. 2018 Sep 28;286:254-263.|J Exp Clin Cancer Res. 2021 Aug 27;40 (1) :273.|J Med Chem. 2025 Mar 13;68 (5) :5907-5925.|J Neuroinflammation. 2023 Jan 17;20 (1) :10.|medRxiv. 2023 Mar 17.|Nat Commun. 2022 Aug 4;13 (1) :4534.|Nature. 2022 Aug;608 (7923) :609-617.|NPJ Precis Oncol. 2021 Jul 16;5 (1) :66.|Obesity (Silver Spring) . 2019 Mar;27 (3) :399-408.|Oncogene. 2016 Apr 28;35 (17) :2247-65.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20220175722A1.|Pharmaceutics. 2025 Oct 31;17 (11) :1415.|Res Sq. 2025 Jul 24.|RSC Adv. 2020,10, 16231-16244.|Sci Rep. 2016 Apr 28;6:25272.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2025 Nov 3;10 (1) :360.|Signal Transduct Target Ther. 2025 Nov 4;10 (1) :361.|The 22nd National Graduate Research Conference. 2021 Mar 25.|Thorac Cancer. 2025 Jan;16 (1) :e15488.|Tissue Eng Part A. 2019 Mar;25 (5-6) :437-445.|University of Auckland. 2025.|World J Exp Med. 2025 Jun 20;15 (2) :100443.